First in class novel inhibitors targeting a central pathway in fibrosis and inflammation
Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.
Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute ,and the Monash Institute of Pharmaceutical Sciences.
IP Group helped spin-out the company and provided seed investment.
Fibrosis is a global problem with high unmet need
deaths linked to fibrosis
of the population have a fibrotic condition
drugs able to reverse fibrosis